AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11532204 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall student satisfaction with search speed
Number of subjects: 0
Study 9694028 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine (30 mg)
Number of subjects: 23
Study 9694028 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (2 mg)
Number of subjects: 23
Study 9694028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7831873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac laser light irradiation of blood
Number of subjects: 172
Study 3071459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 10 to 30 mg twice daily
Number of subjects: 277
Study 3071459 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 20 to 40 mg 3 times daily
Number of subjects: 277
Study 31050660 — intervention group
Group type: EXPERIMENTAL
Intervention: GR mirror therapy
Number of subjects: 36
Study 31050660 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional mirror therapy
Number of subjects: 36
Study 31050660 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 27600789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement with adjunct antimicrobial photodynamic therapy (aPDT)
Number of subjects: 166
Study 27600789 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement alone
Number of subjects: 166
Study 23999422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly titrated oral misoprostol
Number of subjects: 160
Study 23999422 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone 10 mg vaginal insert
Number of subjects: 160
Study 22094327 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT dose of 70.2 Gy
Number of subjects: 114
Study 22094327 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT dose of 79.2 Gy
Number of subjects: 114
Study 22094327 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA half life ratio
Number of subjects: 114
Study 20097532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp technique
Number of subjects: 110
Study 18222415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-relevant CSs with different contexts during extinction
Number of subjects: 136
Study 18222415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-irrelevant CSs with different contexts during extinction
Number of subjects: 136
Study 18222415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-relevant stimuli with indoor office context for acquisition and outdoor bush context for extinction
Number of subjects: 136
Study 18222415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-irrelevant stimuli with outdoor bush context for acquisition and indoor office context for extinction
Number of subjects: 136
Study 15922815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/Ibuprofen 400 mg
Number of subjects: 249
Study 15922815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 15922815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/Acetaminophen 325 mg
Number of subjects: 249
Study 15922815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone 7.5 mg/Acetaminophen 500 mg
Number of subjects: 249
Study 12533165 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport, 100 U dissolved in 0.9% sodium chloride solution)
Number of subjects: 16
Study 12533165 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (control)
Number of subjects: 16
Study 10508209 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triacylglycerols containing predominantly stearic acid
Number of subjects: 14
Study 10508209 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triacylglycerols containing predominantly oleic acid
Number of subjects: 14
Study 10508209 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triacylglycerols (both types)
Number of subjects: 14
Study 8646728 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.)
Number of subjects: 158
Study 8646728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2 i.v.), Epirubicin (60 mg/m2 i.v.), Vindesine (3 mg/m2 i.v.) + Lonidamine (75 mg orally three times on Day 1 to 150 mg orally three times on Day 7+)
Number of subjects: 158
Study 8096416 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 200 micrograms
Number of subjects: 12
Study 8096416 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 8096416 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms
Number of subjects: 12
Study 8096416 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 100 micrograms
Number of subjects: 12
Study 8096416 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol (mean 6.4)
Number of subjects: 12
Study 2950676 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis plus immediate PTCA
Number of subjects: 411
Study 2950676 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 411
Study 2950676 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 411
Study 2950676 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PTCA without prior thrombolysis
Number of subjects: 411
Study 29714034 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral CBD
Number of subjects: 30
Study 29714034 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (PBO)
Number of subjects: 30
Study 24825515 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI‐Creat+CysC)
Number of subjects: 257
Study 24825515 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(MDRD)
Number of subjects: 257
Study 24825515 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI‐Creat)
Number of subjects: 257
Study 24825515 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(CKD‐EPI‐CysC)
Number of subjects: 257
Study 24825515 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐EPI models
Number of subjects: 257
Study 22488276 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic eccentric training (n = 11)
Number of subjects: 21
Study 22488276 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic eccentric training (n = 10)
Number of subjects: 21
Study 20107498 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP1(42)-C1/Alhydrogel + CPG 7909
Number of subjects: 60
Study 20107498 — intervention group
Group type: COMPARATOR
Intervention: MSP1(42)-C1/Alhydrogel
Number of subjects: 60
Study 17882808 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate (1 g/day) in addition to basic therapy
Number of subjects: 60
Study 17882808 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 60
Study 15635344 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols/stanols (2 g/day) incorporated into margarine (25 g/day)
Number of subjects: 25
Study 15635344 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Control group)
Number of subjects: 25
Study 11850150 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/kg metachlorophenylpiperazine (m‐CPP)
Number of subjects: 15
Study 11850150 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ipsapirone
Number of subjects: 15
Study 11850150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10049408 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐EGD
Number of subjects: 60
Study 10049408 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐EGD
Number of subjects: 60
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive feature judgments on upright faces
Number of subjects: 0
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive trait judgments on upright faces
Number of subjects: 0
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive expression judgments on upright faces
Number of subjects: 0
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive feature judgments on inverted faces
Number of subjects: 0
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive trait judgments on inverted faces
Number of subjects: 0
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinctive expression judgments on inverted faces
Number of subjects: 0
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright faces
Number of subjects: 0
Study 9183986 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted faces
Number of subjects: 0
Study 2700360 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-01 treated site
Number of subjects: 0
Study 2700360 — intervention group
Group type: COMPARATOR
Intervention: Placebo treated site
Number of subjects: 0
Study 2700360 — intervention group
Group type: COMPARATOR
Intervention: Control site
Number of subjects: 0
Study 1092514 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (7.3 mg/kg per dose administered every 6 hr)
Number of subjects: 23
Study 1092514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (alone or in combination with theophylline and hydroxyzine)
Number of subjects: 23
Study 1092514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine-theophylline combinations (with and without hydroxyzine)
Number of subjects: 23
Study 1092514 — intervention group
Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 23
Study 1092514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine-theophylline combinations
Number of subjects: 23
Study 30773497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg daily
Number of subjects: 38
Study 30773497 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 38
Study 29070048 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal estimation methods
Number of subjects: 0
Study 29070048 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat analysis
Number of subjects: 0
Study 29070048 — intervention group
Group type: COMPARATOR
Intervention: Per-protocol or as-treated analyses
Number of subjects: 0
Study 25899697 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 25899697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22882740 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1.53 g EPA and 0.31 g DHA per 1000 kcal ME)
Number of subjects: 16
Study 22882740 — intervention group
Group type: COMPARATOR
Intervention: Corn oil supplementation (0.00 g EPA and 0.00 g DHA per 1000 kcal ME)
Number of subjects: 16
Study 21569165 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + CCTA
Number of subjects: 60
Study 21569165 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 60
Study 18366244 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits (1-hour long)
Number of subjects: 1433
Study 16848893 — intervention group
Group type: EXPERIMENTAL
Intervention: r-FSH
Number of subjects: 260
Study 16848893 — intervention group
Group type: COMPARATOR
Intervention: HP-uFSH
Number of subjects: 260
Study 12603251 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF total-tau (T-tau)
Number of subjects: 44
Study 12603251 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF phospho-tau (P-tau)
Number of subjects: 44
Study 12603251 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF A beta 42
Number of subjects: 44
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsant sodium channel blockers
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (anticonvulsant calcium channel blocker)
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (mixed opioid and monoaminergic drug)
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (NMDA-antagonist)
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 11061244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (antiarrhythmic sodium channel blocker)
Number of subjects: 0
Study 9112896 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection
Number of subjects: 14
Study 9112896 — intervention group
Group type: COMPARATOR
Intervention: Drainage
Number of subjects: 14
Study 8356370 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual treatment with steroid injections
Number of subjects: 101
Study 8356370 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (standardized conventional but optimized activating treatment)
Number of subjects: 101
Study 3533909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 70
Study 3533909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29665493 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily positive events
Number of subjects: 200
Study 29665493 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily stressful events
Number of subjects: 200
Study 27316778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Tenofovir Gel
Number of subjects: 24
Study 27316778 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl Cellulose (HEC) - Control
Number of subjects: 24
Study 25190226 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin and insulin
Number of subjects: 179
Study 25190226 — intervention group
Group type: COMPARATOR
Intervention: Placebo and insulin
Number of subjects: 179
Study 21308859 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day residential course of lectures, discussions and peer groups on issues related to treatment and living with cancer
Number of subjects: 507
Study 21308859 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 507
Study 20029715 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless (EL) learning and spaced retrieval (SR)
Number of subjects: 22
Study 20029715 — intervention group
Group type: COMPARATOR
Intervention: Errorful (EF) learning paradigm
Number of subjects: 22
Study 18669424 — intervention group
Group type: COMPARATOR
Intervention: D2 lymphadenectomy alone
Number of subjects: 523
Study 18669424 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus PAND
Number of subjects: 523
Study 16424293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (10 mg twice daily)
Number of subjects: 32
Study 16424293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15071260 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin
Number of subjects: 0
Study 15071260 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin/oral phenprocoumon
Number of subjects: 0
Study 10584042 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified milk fat
Number of subjects: 21
Study 10584042 — intervention group
Group type: COMPARATOR
Intervention: Regular milk fat
Number of subjects: 21
Study 10584042 — intervention group
Group type: COMPARATOR
Intervention: Nonhydrogenated margarine
Number of subjects: 21
Study 8843558 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet of environmentally contaminated Lake Ontario salmon
Number of subjects: 0
Study 8843558 — intervention group
Group type: COMPARATOR
Intervention: Relatively uncontaminated Pacific Ocean salmon
Number of subjects: 0
Study 8843558 — intervention group
Group type: COMPARATOR
Intervention: No salmon
Number of subjects: 0
Study 1913409 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder group
Number of subjects: 5883
Study 1913409 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter reminder group
Number of subjects: 5883
Study 1913409 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminder group
Number of subjects: 5883
Study 1913409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5883
Study 6978871 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 0
Study 31952249 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement containing Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium bifidum, and a galactooligosaccharide mixture; duration: 3 months.
Number of subjects: 20
Study 31952249 — intervention group
Group type: COMPARATOR
Intervention: Placebo; duration: 3 months.
Number of subjects: 20
Study 31952249 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement;
Number of subjects: 20
Study 31952249 — intervention group
Group type: COMPARATOR
Intervention: Placebo;
Number of subjects: 20
Study 30911782 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX followed by DXA screening
Number of subjects: 30719
Study 30911782 — intervention group
Group type: COMPARATOR
Intervention: Usual care (opportunistic screening)
Number of subjects: 30719
Study 29941151 — intervention group
Group type: EXPERIMENTAL
Intervention: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg after a 10-hour overnight fast
Number of subjects: 13
Study 29941151 — intervention group
Group type: COMPARATOR
Intervention: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg 30 minutes after a high-fat breakfast
Number of subjects: 13
Study 27357103 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU per week)
Number of subjects: 511
Study 27357103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 25756831 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC aclidinium 400 μg/formoterol 12 μg (ACL400/FOR12 FDC)
Number of subjects: 1692
Study 25756831 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC aclidinium 400 μg/formoterol 6 μg (ACL400/FOR6 FDC)
Number of subjects: 1692
Study 25756831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1692
Study 21937686 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% target blood alcohol concentration)
Number of subjects: 0
Study 21937686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19723906 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD adherence measured by Compliance Questionnaire on Rheumatology (CQR)
Number of subjects: 228
Study 19723906 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD adherence measured by Medication Adherence Scale (MARS)
Number of subjects: 228
Study 19723906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence risk factors
Number of subjects: 228
Study 19723906 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration, perceived side-effects, beliefs about necessity of medicine
Number of subjects: 228
Study 19723906 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall nonadherence rate
Number of subjects: 228
Study 17703139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan + Furosemide
Number of subjects: 12
Study 17703139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan + HCTZ
Number of subjects: 12
Study 17703139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan alone
Number of subjects: 12
Study 17703139 — intervention group
Group type: COMPARATOR
Intervention: Furosemide or HCTZ administered alone
Number of subjects: 12
Study 17703139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan + Furosemide or HCTZ
Number of subjects: 12
Study 15385638 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium intake (ad libitum)
Number of subjects: 12
Study 15385638 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake (<5 g/day)
Number of subjects: 12
Study 15385638 — intervention group
Group type: COMPARATOR
Intervention: High sodium intake (100 mg/kg/day)
Number of subjects: 12
Study 11430631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN-alpha (Group A)
Number of subjects: 128
Study 11430631 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant 2a IFN-alpha (Group B)
Number of subjects: 128
Study 11430631 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant 2b IFN-alpha (Group C)
Number of subjects: 128
Study 11430631 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte IFN-alpha (Group D)
Number of subjects: 128
Study 9951054 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 0
Study 9951054 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 0
Study 7886394 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxicillin (40 mg or 80 mg) for 1- or 2-week regimens
Number of subjects: 423
Study 7886394 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxicillin
Number of subjects: 423
Study 3061773 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental anaesthesia
Number of subjects: 20
Study 29192741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib or pazopanib
Number of subjects: 270
Study 29192741 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive nephrectomy (CN) followed by sunitinib or pazopanib
Number of subjects: 270
Study 27517517 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP)
Number of subjects: 45
Study 27517517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25775747 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 150
Study 25775747 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 150
Study 25775747 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver combined with Semont maneuver
Number of subjects: 150
Study 22851113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (goal of 90 min/wk for months 1‐3 followed by home exercise with a goal of ≥120 min/wk for months 4‐12)
Number of subjects: 2322
Study 22851113 — intervention group
Group type: COMPARATOR
Intervention: Usual care (education and usual guideline‐based heart failure care)
Number of subjects: 2322
Study 22851113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 2322